AddThis Sharing Buttons
Published October 6, 2017 by Joseph Gustaitis
Print Text Size: A A A
Many people with diabetes want to test their blood sugar levels regularly but don’t. The reason that most of them give is that they just don’t want to go through the unpleasant business of sticking their finger to draw blood. However, the U.S. Food and Drug Administration (FDA) has just approved a new technology that its manufacturer advertises as a breakthrough that “eliminates the need for routine fingersticks.”
The device is called the FreeStyle Libre Flash Glucose Monitoring System (FreeStyle Libre for short), and it’s the creation of Abbott, a global health-care company based in Illinois. The system checks blood glucose levels through a sensor that’s about the size of two stacked quarters. The user applies the waterproof sensor to the back of the upper arm. Once it’s in place, the user is able to scan it with a small handheld reader. The scan is painless and takes about a second. Because the scanner can make readings through clothing, the wearer doesn’t have to uncover the upper arm to get a reading.
Advertisement
.
The scan identifies glucose levels as high, low, or stable and provides an 8-hour history of fluctuations — in other words, the FreeStyle Libre essentially works as a continuous glucose monitor (CGM). The manufacturer says that the FreeStyle Libre is calibrated at the factory and therefore doesn’t require daily calibration by the user through fingersticks, as some other CGMs do. The device is especially recommended for people being treated with insulin, because these are the ones who require the most careful and frequent monitoring.
Although it has just been approved in the United States, the FreeStyle Libre has already been used by more than 400,000 people in about 40 countries. The manufacturer says reports indicate that users test their glucose levels at an average of at least 15 times a day, a frequency that leads to better overall glucose control. Abbott expects that the device will be available at U.S. pharmacies before the end of the year. To get one, a user will need a doctor’s prescription.
Recent ABT News
- Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee • PR Newswire (US) • 04/29/2024 01:00:00 PM
- Abbott Laboratories Reports Strong Q1 Sales Growth Amid Earnings Decline, Raises Full-Year Guidance • IH Market News • 04/17/2024 03:37:57 PM
- Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges • PR Newswire (US) • 04/17/2024 11:30:00 AM
- US Index Futures See Gains, Oil Prices Dip • IH Market News • 04/17/2024 10:59:02 AM
- Cal-Maine Surges on Strong Quarterly Performance, Taiwan Earthquake Disrupts Tech Supply Chain, and More • IH Market News • 04/03/2024 11:12:20 AM
- Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve • PR Newswire (US) • 04/02/2024 01:00:00 PM
- Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside • PR Newswire (US) • 04/01/2024 01:00:00 PM
- Abbott Hosts Conference Call for First-Quarter Earnings • PR Newswire (US) • 03/27/2024 08:30:00 PM
- Une première au Canada -- Abbott fait progresser le traitement de la douleur chronique grâce au plus petit système de stimulation de la moelle épinière implantée et rechargeable au monde • PR Newswire (Canada) • 03/19/2024 12:00:00 PM
- Canadian First - Abbott Advances Chronic Pain Management with the World's Smallest Implanted, Rechargeable Spinal Cord Stimulation System • PR Newswire (Canada) • 03/19/2024 12:00:00 PM
- Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes • PR Newswire (US) • 03/06/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:22:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:18:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:14:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:09:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:05:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:00:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:56:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:50:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:44:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:39:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:53:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:45:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:39:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:32:58 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM